Posted On: 06/07/2014 12:09:04 AM
Post# of 53
ZENO News Friday, June 6, 2014 11:09:29 PM $ZENO
Zenosense, Inc. Highlights Recent Media Coverage of MRSA
Marketwire - Tue May 27, 7:31AM CDT
Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"
, a healthcare technology company focused on developing and marketing a device for use in hospitals and other healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug," notes a number of recent and relevant articles in the media regarding MRSA and Super-Bugs.
Zenosense, Inc. Provides Development Update
Marketwire - Wed May 21, 7:30AM CDT
Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company", a healthcare technology company focused on developing and marketing a device for use in hospitals and other healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug," is pleased to announce that based on data and information provided by and reviews with Zenon Biosystem considerable progress has been made since signing the development agreement six months ago.
Zenosense, Inc. Extends License to Include Cancer Applications
Marketwire - Thu May 08, 7:31AM CDT
Zenosense, Inc. (OTCQB: ZENO) (the "Company", a healthcare technology company focused on developing and marketing a device for use in hospitals and other healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug," is pleased to announce that the Company has extended its agreement with the Sgenia Group ("Sgenia" to include cancer sensory devices.
Zenosense, Inc. Enters Into $475,000 Securities Purchase Agreement
Marketwire - Thu Apr 10, 8:28AM CDT
Zenosense, Inc. (OTCQB: ZENO) (the "Company", a healthcare technology company focused on developing and marketing a device for use in hospitals and other healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug," is pleased to announce that the Company has entered into a securities purchase agreement ("Agreement" for the sales of shares to an accredited investor ("Investor" under the provisions of Section 4(2) of the Securities Act of 1933, as amended.
Zenosense, Inc. Highlights Recent Media Coverage of MRSA
Marketwire - Tue May 27, 7:31AM CDT
Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"
, a healthcare technology company focused on developing and marketing a device for use in hospitals and other healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug," notes a number of recent and relevant articles in the media regarding MRSA and Super-Bugs. Zenosense, Inc. Provides Development Update
Marketwire - Wed May 21, 7:30AM CDT
Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"
, a healthcare technology company focused on developing and marketing a device for use in hospitals and other healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug," is pleased to announce that based on data and information provided by and reviews with Zenon Biosystem considerable progress has been made since signing the development agreement six months ago. Zenosense, Inc. Extends License to Include Cancer Applications
Marketwire - Thu May 08, 7:31AM CDT
Zenosense, Inc. (OTCQB: ZENO) (the "Company"
, a healthcare technology company focused on developing and marketing a device for use in hospitals and other healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug," is pleased to announce that the Company has extended its agreement with the Sgenia Group ("Sgenia" to include cancer sensory devices. Zenosense, Inc. Enters Into $475,000 Securities Purchase Agreement
Marketwire - Thu Apr 10, 8:28AM CDT
Zenosense, Inc. (OTCQB: ZENO) (the "Company"
, a healthcare technology company focused on developing and marketing a device for use in hospitals and other healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug," is pleased to announce that the Company has entered into a securities purchase agreement ("Agreement" for the sales of shares to an accredited investor ("Investor" under the provisions of Section 4(2) of the Securities Act of 1933, as amended. 
(0)
(0)
